Your browser doesn't support javascript.
loading
Association of Obesity-Related Metabolic Disruptions With Cancer Risk and Outcome.
Lohmann, Ana Elisa; Goodwin, Pamela J; Chlebowski, Rowan T; Pan, Kathy; Stambolic, Vuk; Dowling, Ryan J O.
Afiliação
  • Lohmann AE; Ana Elisa Lohmann and Pamela J. Goodwin, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto; Vuk Stambolic, University of Toronto; Vuk Stambolic and Ryan J.O. Dowling, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; and Rowan T.
  • Goodwin PJ; Ana Elisa Lohmann and Pamela J. Goodwin, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto; Vuk Stambolic, University of Toronto; Vuk Stambolic and Ryan J.O. Dowling, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; and Rowan T.
  • Chlebowski RT; Ana Elisa Lohmann and Pamela J. Goodwin, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto; Vuk Stambolic, University of Toronto; Vuk Stambolic and Ryan J.O. Dowling, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; and Rowan T.
  • Pan K; Ana Elisa Lohmann and Pamela J. Goodwin, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto; Vuk Stambolic, University of Toronto; Vuk Stambolic and Ryan J.O. Dowling, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; and Rowan T.
  • Stambolic V; Ana Elisa Lohmann and Pamela J. Goodwin, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto; Vuk Stambolic, University of Toronto; Vuk Stambolic and Ryan J.O. Dowling, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; and Rowan T.
  • Dowling RJ; Ana Elisa Lohmann and Pamela J. Goodwin, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto; Vuk Stambolic, University of Toronto; Vuk Stambolic and Ryan J.O. Dowling, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; and Rowan T.
J Clin Oncol ; 34(35): 4249-4255, 2016 12 10.
Article em En | MEDLINE | ID: mdl-27903146
ABSTRACT
Over the past 40 years, the prevalence of obesity has increased epidemically worldwide, which raises significant concerns regarding public health and the associated economic burden. Obesity is a major risk factor for several conditions including cardiovascular disease and type 2 diabetes, and recent evidence suggests that obesity negatively affects cancer risk and outcome. The relationship between obesity and cancer is complex and involves multiple factors both at the systemic and cellular level. Indeed, disruptions in insulin metabolism, adipokines, inflammation, and sex hormones all contribute to the adverse effects of obesity in cancer development and progression. The focus of this review will be the impact of these systemic obesity-related factors on cancer biology, incidence, and outcome. Potential therapeutic interventions and current clinical trials targeting obesity and its associated factors will also be discussed.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Metabolismo Energético / Neoplasias / Obesidade Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Clin Oncol Ano de publicação: 2016 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Metabolismo Energético / Neoplasias / Obesidade Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Clin Oncol Ano de publicação: 2016 Tipo de documento: Article